Predicting the Long-Term Outcomes of Biologics in Psoriasis Patients Using Machine Learning

Despite the vast amount of data on the efficacy of biologics in psoriasis treatment, therapeutic decision-making is still based on a trial-and-error approach. In a real world setting over 50% of patients needing dose adjustment during therapy and 20-50% of patients experiencing a relapse of the disease requiring a switch to another medication.

[1]  Y. Kitano,et al.  Separation of the epidermal sheet by dispase , 1983, The British journal of dermatology.

[2]  R. Emsley,et al.  Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study , 2018, The British journal of dermatology.

[3]  Ioannis A. Kakadiaris,et al.  Machine Learning Outperforms ACC/AHA CVD Risk Calculator in MESA , 2018, Journal of the American Heart Association.

[4]  A. Valencia,et al.  Somatic Embryonic FGFR2 Mutations in Keratinocytic Epidermal Nevi. , 2016, The Journal of investigative dermatology.

[5]  M. Landthaler,et al.  Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort , 2011, Experimental dermatology.

[6]  Joseph G Ibrahim,et al.  Basic concepts and methods for joint models of longitudinal and survival data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Naldi,et al.  Psoriasis registries worldwide: systematic overview on registry publications , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  L. Skov,et al.  Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris , 2011, The British journal of dermatology.

[9]  L. Skov,et al.  Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris , 2015, The British journal of dermatology.

[10]  M. Landthaler,et al.  Low Incidence of Oncogenic EGFR, HRAS, and KRAS Mutations in Seborrheic Keratosis , 2014, The American Journal of dermatopathology.

[11]  Kenneth L Kehl,et al.  Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. , 2019, JAMA oncology.

[12]  N. Malats,et al.  Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors , 2010, Proceedings of the National Academy of Sciences.

[13]  Kurt Lohman,et al.  Interpreting measures of treatment effect in cancer clinical trials. , 2002, The oncologist.

[14]  M. Motwani,et al.  Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease: a 5-year multicentre prospective registry analysis , 2016, European heart journal.

[15]  Subhashini Venugopalan,et al.  Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. , 2016, JAMA.

[16]  Riccardo Bellazzi,et al.  Machine Learning Methods to Predict Diabetes Complications , 2018, Journal of diabetes science and technology.

[17]  F. Real,et al.  Keratinocytic epidermal nevi are associated with mosaic RAS mutations , 2012, Journal of Medical Genetics.

[18]  Gustavo Henrique Goulart Trossini,et al.  Use of machine learning approaches for novel drug discovery , 2016, Expert opinion on drug discovery.

[19]  C. Peschel,et al.  The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  A. Burden,et al.  Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR , 2018, JAMA dermatology.

[21]  K. Borgwardt,et al.  Machine Learning in Medicine , 2015, Mach. Learn. under Resour. Constraints Vol. 3.

[22]  D. Morgan,et al.  Assessment of Machine Learning vs Standard Prediction Rules for Predicting Hospital Readmissions , 2019, JAMA network open.

[23]  D. Altman,et al.  Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.

[24]  M. Kivimäki,et al.  5-year versus risk-category-specific screening intervals for cardiovascular disease prevention: a cohort study , 2019, The Lancet. Public health.

[25]  B. Davis,et al.  Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus. , 2019, European heart journal.

[26]  L. Skov,et al.  Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis , 2018, The British journal of dermatology.

[27]  N. Reynolds,et al.  Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis : Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register ( BADBIR ) 74 75 76 , 2017 .

[28]  Michael Landthaler,et al.  Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. , 2006, The Journal of clinical investigation.

[29]  B. Kiely,et al.  How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Eric R. Ziegel,et al.  Generalized Linear Models , 2002, Technometrics.